title: [Current development status and prospect of dual PI3K/mTOR inhibitors for cancer therapy].
authors.forename: Yoshinobu
authors.initials: Y
authors.lastname: Shiose
mesh_terms: D014408:Biomarkers, Tumor; D019086:Bridged Bicyclo Compounds, Heterocyclic / Q000008:administration & dosage; D058534:Class I Phosphatidylinositol 3-Kinases; D002986:Clinical Trials as Topic; D055808:Drug Discovery / Q000639:trends*; D004359:Drug Therapy, Combination; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage; D058990:Molecular Targeted Therapy; D009154:Mutation; D009369:Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology* / Q000235:genetics; D051059:PTEN Phosphohydrolase / Q000235:genetics; D019869:Phosphatidylinositol 3-Kinases / Q000235:genetics / Q000502:physiology; D000081082:Phosphoinositide-3 Kinase Inhibitors; D011743:Pyrimidines / Q000008:administration & dosage; D011804:Quinolines / Q000008:administration & dosage; D058570:TOR Serine-Threonine Kinases / Q000037:antagonists & inhibitors* / Q000502:physiology
chemical_list: D014408:Biomarkers, Tumor; D019086:Bridged Bicyclo Compounds, Heterocyclic; D058534:Class I Phosphatidylinositol 3-Kinases; D007093:Imidazoles; D051059:PTEN Phosphohydrolase; D019869:Phosphatidylinositol 3-Kinases; D000081082:Phosphoinositide-3 Kinase Inhibitors; D011743:Pyrimidines; D011804:Quinolines; D058570:TOR Serine-Threonine Kinases; C569670:1-(4-((2-(2-aminopyrimidin-5-yl)-7-methyl-4-morpholinothieno(3,2-d)pyrimidin-6-yl)methyl)piperazin-1-yl)-2-hydroxypropan-1-one; C484760:PIK3CA protein, human; C494929:PTEN protein, human; C531198:dactolisib